We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
- Authors
Masuda, N; Fukuoka, M; Kudoh, S; Matsui, K; Kusunoki, Y; Takada, M; Nakagawa, K; Hirashima, T; Tsukada, H; Yana, T
- Abstract
We conducted a phase I trial of irinotecan (CPT-11), a topoisomerase I inhibitor, combined with etoposide, a topoisomerase II inhibitor, and recombinant human granulocyte colony-stimulating factor (rhG-CSF) support because of the overlapping neutrophil toxicity of both drugs. The aim was to determine the maximum-tolerated dose of CPT-11 combined with a fixed dose of etoposide in patients with advanced lung cancer, as well as the dose-limiting toxicities of this combination.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Vol 12, Issue 9, p1833
- ISSN
0732-183X
- Publication type
Journal Article
- DOI
10.1200/JCO.1994.12.9.1833